Holen Sie sich die Stockscreener-App
19.15
1.70%
-0.3097
Schlusskurs vom Vortag:
$19.46
Offen:
$19.44
24-Stunden-Volumen:
121.30K
Relative Volume:
0.14
Marktkapitalisierung:
$582.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-3.733
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
+1.43%
1M Leistung:
-10.52%
6M Leistung:
+32.57%
1J Leistung:
+59.15%
1-Tages-Spanne:
$19.12
$19.94
1-Wochen-Bereich:
$18.33
$19.94
52-Wochen-Spanne:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
19.13 | 592.87M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.41 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.53 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.01 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.15 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Nasdaq
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - sharewise.com
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - sharewise.com
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
(KROS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
Downgrade Watch: What’s the RSI of Keros Therapeutics Inc. stock2025 Performance Recap & Long-Term Safe Investment Plans - baoquankhu1.vn
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz
Aug Technicals: Is Keros Therapeutics Inc likely to announce a buybackJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn
History Review: What are Keros Therapeutics Incs technical support levelsJuly 2025 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Aug Patterns: What is the next catalyst for Keros Therapeutics IncWeekly Trade Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - Zacks Investment Research
MACD Signal: Whats the fair value of Keros Therapeutics Inc stock2025 Key Highlights & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced - Finviz
Keros Therapeutics, Inc. (KROS) Stock Analysis: Strong Revenue Growth and a 26% Potential Upside - DirectorsTalk Interviews
Will Keros Therapeutics Inc. stock outperform value stocks2025 Macro Impact & Weekly Breakout Opportunity Watchlist - Улправда
How rising interest rates impact Keros Therapeutics Inc. stockJuly 2025 Chart Watch & Verified Stock Trade Ideas - Улправда
What analysts say about Keros Therapeutics Inc stockSector Rotation Strategies & Real-Life Case Studies You Can Follow - earlytimes.in
Bank of America Securities Keeps Their Hold Rating on Keros Therapeutics (KROS) - The Globe and Mail
Keros Therapeutics (NASDAQ:KROS) Trading Down 3.3% on Analyst Downgrade - Defense World
Keros Therapeutics (NASDAQ:KROS) Cut to “Hold” at Zacks Research - Defense World
(KROS) Risk Channels and Responsive Allocation - Stock Traders Daily
Keros Therapeutics (NASDAQ:KROS) Downgraded to Hold Rating by Zacks Research - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.3%Time to Sell? - MarketBeat
Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics - Yahoo Finance
Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Drops By 16.6% - MarketBeat
5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close - Yahoo Finance
KROS or ARGX: Which Is the Better Value Stock Right Now? - sharewise.com
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Keros Therapeutics Reports Strong Revenue Growth - MSN
Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily
Assenagon Asset Management S.A. Has $4.07 Million Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Keros Therapeutics (NASDAQ:KROS) Raised to “Hold” at TD Cowen - Defense World
Keros Therapeutics (NASDAQ:KROS) Upgraded at TD Cowen - MarketBeat
Can Keros Therapeutics Inc. stock deliver consistent earnings growthJuly 2025 Chart Watch & Fast Gaining Stock Reports - Улправда
Keros Therapeutics (NASDAQ:KROS) Trading Down 3.7%Here's Why - MarketBeat
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 - The Globe and Mail
Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros - sharewise.com
Keros Therapeutics Earnings Notes - Trefis
TFG Asset Management GP Ltd Sells 55,000 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares - MSN
Responsive Playbooks and the KROS Inflection - Stock Traders Daily
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.31%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):